Skip to main content
. Author manuscript; available in PMC: 2024 Apr 5.
Published in final edited form as: Neuron. 2023 Jan 19;111(7):1086–1093.e2. doi: 10.1016/j.neuron.2022.12.029

Table 1:

Summary of Participants in the Study

FinnGen (discovery phase) UKB (replication phase)
NDD All Female Male All Female Male
AD 9301 4079 5222 2342 1199 1143
ALS 483 181 302 357 209 148
dementia 16,499 6984 9515 2200 981 1219
MS 2182 1648 534 1349 985 364
PD 4235 1658 2577 2998 1106 1892
vascular 2335 778 1557 430 152 278
controls 309,154 173,746 135,408 96,390 48,919 47,471

Summary of participants analyzed in this study that includes over 400,000 samples across two national biobanks. In FinnGen, the control numbers listed below are the general population count (total); in the UKB these include exclusions described in the methods section such as concurrent neurodegenerative disease diagnoses.